AzTrials
AzTrials

Coronary Artery DiseaseBITA-SURVNCT07796750

Extensive BITA Grafting in the Canary Islands: an IPTW Analysis

An observational study of Coronary Artery Disease and Coronary Artery Bypass Grafting, run by Hospital Universitario de Gran Canaria Doctor Negrín at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Coronary artery bypass grafting (CABG) remains the preferred revascularization strategy for patients with complex multivessel coronary artery disease. The left internal thoracic artery is universally accepted as the standard conduit for grafting the left anterior descending artery, but the long-term clinical benefit… Read more about this study

Who is it for?
Ages 18 years and older
How many people
666 participants
Where
1 siteSpain
Study dates
1 Jan 2024to 30 Jun 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult patients undergoing first-time isolated coronary artery bypass grafting in whom at least two coronary artery grafts were performed. Patients undergoing a single coronary artery graft were excluded.

Who may be able to join

  • Age 18 years or older.
  • First-time isolated coronary artery bypass grafting.
  • At least two coronary artery grafts performed.
  • Surgery performed between May 1, 2017 and October 31, 2025.
  • Complete information regarding surgical grafting strategy.
  • Available follow-up.

Who cannot join

  • Previous coronary artery bypass grafting.
  • Single coronary artery graft only.
  • Concomitant cardiac surgical procedures.
  • Missing information regarding arterial grafting strategy.
  • Missing follow-up data.
  • Missing essential baseline variables preventing propensity score estimation.

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Hospital Universitario de Gran Canaria Dr. Negrin

    Las Palmas de Gran Canaria

Other trials in Spain

About this study

Official title: Implementing a CABG Program Based on Extensive Bilateral Internal Thoracic Artery Use in the Canary Islands: an Inverse Probability of Treatment Weighted Analysis of Survival, Stroke and Sternal Wound Complications

Coronary artery bypass grafting (CABG) remains the preferred revascularization strategy for patients with complex multivessel coronary artery disease. The left internal thoracic artery is universally accepted as the standard conduit for grafting the left anterior descending artery, but the long-term clinical benefit and safety of bilateral internal thoracic artery (BITA) grafting compared with single internal thoracic artery (SITA) grafting remain debated.

This retrospective cohort study compares long-term outcomes after BITA versus SITA grafting in consecutive adult patients undergoing first-time isolated CABG with at least two coronary grafts between May 1, 2017 and October 31, 2025 at Hospital Universitario de Gran Canaria Dr. Negrin. The primary endpoint is all-cause mortality during follow-up. Secondary outcomes include cardiovascular mortality, non-cardiovascular mortality, deep sternal wound infection, stroke, myocardial infarction, repeat coronary revascularization, and major adverse cardiovascular events (MACE).

Treatment groups will be balanced using stabilized inverse probability of treatment weighting derived from a multivariable propensity score model including clinically relevant baseline variables. Long-term outcomes will be analyzed using weighted Kaplan-Meier survival curves and Cox proportional hazards regression.

Read the detailed description

Background and scientific rationale:

Coronary artery disease remains a leading cause of mortality worldwide. Coronary artery bypass grafting is recommended as a preferred revascularization strategy for selected patients with complex multivessel coronary artery disease and left main coronary artery disease because of durable long-term clinical benefits.

Although the left internal thoracic artery graft to the left anterior descending artery has superior long-term patency and survival compared with venous conduits, routine use of bilateral internal thoracic arteries remains limited. Observational studies have suggested improved long-term survival following BITA grafting, whereas randomized evidence has not consistently demonstrated a statistically significant survival advantage in intention-to-treat analyses. Concerns regarding deep sternal wound infection, particularly in patients with diabetes mellitus, obesity, and chronic pulmonary disease, have also limited wider adoption.

Study hypothesis:

The use of bilateral internal thoracic artery grafting is associated with improved long-term survival compared with single internal thoracic artery grafting without increasing the adjusted risk of deep sternal wound infection. Any survival benefit may be primarily explained by a reduction in cardiovascular mortality rather than non-cardiovascular mortality.

Primary objective:

To compare long-term all-cause mortality between patients undergoing bilateral internal thoracic artery grafting and those receiving single internal thoracic artery grafting after adjustment using stabilized inverse probability of treatment weighting.

Secondary objectives:

To compare cardiovascular mortality, non-cardiovascular mortality, deep sternal wound infection, stroke, myocardial infarction, repeat coronary revascularization, major adverse cardiovascular events, early versus late mortality, temporal distribution of mortality, and predictors of deep sternal wound infection.

Statistical analysis plan:

Baseline demographic, clinical, and operative characteristics will be summarized according to arterial revascularization strategy. Continuous variables will be reported as mean with standard deviation or median with interquartile range, depending on distribution. Categorical variables will be reported as frequencies and percentages. Comparisons will use Student t-test or Mann-Whitney U test for continuous variables and Pearson chi-square or Fisher exact test for categorical variables, as appropriate.

Propensity scores will be estimated using multivariable logistic regression representing the conditional probability of receiving BITA grafting. Covariates will include age, sex, body mass index, obesity, diabetes mellitus, chronic obstructive pulmonary disease, current smoking, hypertension, peripheral arterial disease, cerebrovascular disease, chronic dialysis, preoperative cardiac rhythm, serum creatinine greater than 200 micromol/L, left ventricular ejection fraction, left main coronary artery disease, and use of cardiopulmonary bypass.

Stabilized inverse probability of treatment weights will be calculated using the marginal probability of treatment assignment. Balance will be assessed using standardized mean differences, with adequate balance defined as an absolute standardized mean difference less than 0.10.

Overall survival will be estimated using Kaplan-Meier methodology. The primary comparison will be performed using IPTW-adjusted Cox proportional hazards regression and reported as hazard ratios with 95% confidence intervals and two-sided P values. Cause-specific mortality analyses will be performed separately for cardiovascular and non-cardiovascular mortality. Competing-risk regression using the Fine and Gray subdistribution hazards model will be performed when event numbers permit.

Sensitivity analyses will include complete-case analysis, conventional multivariable regression, alternative propensity score specifications, exclusion of patients with very short follow-up, exclusion of deaths with undetermined cause, and multiple imputation analyses if appropriate. Exploratory subgroup analyses will be performed according to age 70 years or older, diabetes mellitus, obesity, chronic obstructive pulmonary disease, reduced left ventricular ejection fraction, left main coronary artery disease, and use versus non-use of cardiopulmonary bypass.

Ethics and data protection:

The study will be conducted in accordance with the Declaration of Helsinki, Good Clinical Practice principles applicable to observational research, European General Data Protection Regulation, Spanish Organic Law 3/2018 on Personal Data Protection, and Spanish Biomedical Research Act Law 14/2007. All patient information will be pseudonymized before analysis.

Keywords
CABG, Bilateral Internal Thoracic Artery, BITA, Single Internal Thoracic Artery, SITA, Multiple Arterial Grafting, Long-Term Survival, Cause-Specific Mortality, Cardiovascular Mortality, Deep Sternal Wound Infection, DSWI, Propensity Score, Inverse Probability of Treatment Weighting, IPTW, Observational Cohort, Cardiac Surgery
Medical subject headings
Coronary Artery Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07796750
Study groupRoleWhat they receive
Bilateral Internal Thoracic Artery Grafting (BITA)Patients receiving bilateral internal thoracic artery grafts as part of the myocardial revascularization procedure. Additional radial artery or saphenous vein grafts could be used whenever required to achieve complete revascularization.
Single Internal Thoracic Artery Grafting (SITA)Patients receiving one internal thoracic artery together with additional saphenous vein and/or radial artery grafts according to surgeon preference.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. All-cause mortality

    Death from any cause occurring after coronary artery bypass graft surgery.

    Measured: From coronary artery bypass graft surgery until death or last available clinical follow-up, with maximum follow-up through October 31, 2025. (107 months)

Secondary outcomes (7)
  1. Cardiovascular mortality

    Death attributable to myocardial infarction, heart failure, sudden cardiac death, fatal arrhythmia, stroke, or other cardiovascular causes.

    Measured: From surgery until death or last available follow-up, with maximum follow-up through October 31, 2025. (107 months)

  2. Non-cardiovascular mortality

    Death secondary to infection, malignancy, renal disease, neurological disease, respiratory disease, gastrointestinal disease, trauma, or other non-cardiovascular causes.

    Measured: From surgery until death or last available follow-up, with maximum follow-up through October 31, 2025. (107 months)

  3. Deep sternal wound infection

    Deep sternal wound infection requiring surgical debridement, vacuum-assisted closure therapy, or both.

    Measured: Postoperative period through available follow-up. (107 months)

  4. Stroke

    Occurrence of postoperative stroke during follow-up.

    Measured: From surgery until last available clinical follow-up, with maximum follow-up through October 31, 2025. (107 months)

  5. Myocardial infarction

    Occurrence of myocardial infarction during follow-up.

    Measured: From surgery until last available clinical follow-up, with maximum follow-up through October 31, 2025. (107 months)

  6. Repeat coronary revascularization

    Need for repeat coronary revascularization by percutaneous coronary intervention or redo coronary artery bypass grafting.

    Measured: From surgery until last available clinical follow-up, with maximum follow-up through October 31, 2025. (107 months)

  7. Major adverse cardiovascular events

    Composite endpoint including all-cause mortality, myocardial infarction, stroke, or repeat coronary revascularization.

    Measured: From surgery until last available clinical follow-up, with maximum follow-up through October 31, 2025. (107 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Sep 2026
  2. Study start1 Jan 2024
  3. Primary completion31 May 2026
  4. Study completion30 Jun 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
666 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07796750
Sponsor's protocol ID
BITA-SURV
Acronym
BITA-SURV
Status last verified
Aug 2026
First submitted
24 Aug 2026
Last updated
1 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Following publication of the primary results, requests for access to de-identified individual participant data may be considered on a case-by-case basis by the principal investigator and sponsoring institution, subject to institutional policies, ethical approval, and applicable data protection regulations.

Questions about this trial

What is this clinical trial studying?

An observational study of Coronary Artery Disease and Coronary Artery Bypass Grafting, run by Hospital Universitario de Gran Canaria Doctor Negrín at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

All-cause mortality (time frame: From coronary artery bypass graft surgery until death or last available clinical follow-up, with maximum follow-up through October 31, 2025. (107 months)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in